Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

NCT00708721 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Data analysis revealed sufficient data for safety and efficacy

Conditions

Cancer
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Clofarabine

Sponsor

University of Utah

Collaborators

[object Object]